Advertisement
INBS vs PRPO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INBS is a Buy and PRPO is a Buy.
INBS in upward trend: 10-day moving average broke above 50-day moving average on November 09, 2026
The 10-day moving average for INBS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INBS as a result. In 70 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for INBS just turned positive on October 16, 2026. Looking at past instances where INBS's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.
INBS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +30.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBS advanced for three days, in 153 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 42 of 56 cases where INBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for INBS moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 18 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 32 cases where INBS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INBS broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.186) is normal, around the industry mean (4.142). P/E Ratio (-0.233) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.688) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. INBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PRPO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PRPO turned positive on November 06, 2026. Looking at past instances where PRPO's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on PRPO as a result. In 81 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
PRPO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRPO advanced for three days, in 195 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for PRPO moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 18 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for PRPO moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRPO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
PRPO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRPO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.259) is normal, around the industry mean (67.298). P/E Ratio (-30.032) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.715) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. PRPO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRPO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
INBS | PRPO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 93 | |
PRICE GROWTH RATING 1..100 | 61 | 45 | |
P/E GROWTH RATING 1..100 | 44 | 21 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRPO's Valuation (29) in the Biotechnology industry is in the same range as INBS (42) in the null industry. This means that PRPO’s stock grew similarly to INBS’s over the last 12 months.
PRPO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INBS (100) in the null industry. This means that PRPO’s stock grew similarly to INBS’s over the last 12 months.
PRPO's SMR Rating (93) in the Biotechnology industry is in the same range as INBS (100) in the null industry. This means that PRPO’s stock grew similarly to INBS’s over the last 12 months.
PRPO's Price Growth Rating (45) in the Biotechnology industry is in the same range as INBS (61) in the null industry. This means that PRPO’s stock grew similarly to INBS’s over the last 12 months.
PRPO's P/E Growth Rating (21) in the Biotechnology industry is in the same range as INBS (44) in the null industry. This means that PRPO’s stock grew similarly to INBS’s over the last 12 months.
| INBS | PRPO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| Advances ODDS (%) | 5 days ago 84% | 3 days ago 81% |
| Declines ODDS (%) | 1 day ago 90% | 12 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INBS’s FA Score shows that 0 FA rating(s) are green while PRPO’s FA Score has 2 green FA rating(s).
- INBS’s FA Score: 0 green, 5 red.
- PRPO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INBS’s TA Score shows that 6 TA indicator(s) are bullish while PRPO’s TA Score has 4 bullish TA indicator(s).
- INBS’s TA Score: 6 bullish, 4 bearish.
- PRPO’s TA Score: 4 bullish, 6 bearish.
Price Growth
INBS (@Medical/Nursing Services) experienced а +10.23% price change this week, while PRPO (@Medical Specialties) price change was +25.07% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.08%. For the same industry, the average monthly price growth was -5.52%, and the average quarterly price growth was -4.54%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.23%. For the same industry, the average monthly price growth was -5.93%, and the average quarterly price growth was +36.61%.
Reported Earning Dates
INBS is expected to report earnings on Feb 18, 2027.
Industries' Descriptions
@Medical/Nursing Services (+2.08% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-0.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
INBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, INBS has been loosely correlated with IVF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if INBS jumps, then IVF could also see price increases.
| Ticker / NAME | Correlation To INBS | 1D Price Change % | ||
|---|---|---|---|---|
| INBS | 100% | -7.62% | ||
| IVF - INBS | 63% Loosely correlated | -0.19% | ||
| ELMD - INBS | 31% Poorly correlated | +0.04% | ||
| NVNO - INBS | 27% Poorly correlated | +0.84% | ||
| ITGR - INBS | 27% Poorly correlated | -0.21% | ||
| PFSA - INBS | 26% Poorly correlated | -16.36% | ||
More | ||||
PRPO and
Correlation & Price change
A.I.dvisor tells us that PRPO and TNON have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRPO and TNON's prices will move in lockstep.
| Ticker / NAME | Correlation To PRPO | 1D Price Change % | ||
|---|---|---|---|---|
| PRPO | 100% | -6.25% | ||
| TNON - PRPO | 27% Poorly correlated | +2.58% | ||
| INGN - PRPO | 25% Poorly correlated | -2.26% | ||
| XAIR - PRPO | 25% Poorly correlated | -16.16% | ||
| INBS - PRPO | 24% Poorly correlated | -7.62% | ||
| BEAT - PRPO | 24% Poorly correlated | -1.78% | ||
More | ||||